KFDA Approves Atacand for Treatment of Heart Failure

Published: 2005-04-06 06:58:00

Updated: 2005-04-06 06:58:00

AstraZeneca Korea announced that Atacand (candesarten cilexetil), an angiotensin receptor blocker (ARB) for the treatment of hypertension, has been approved by the Korea Food and Drug Administration (KFDA) for the treatment of heart failure to reduce the cardiovascular mortality and hospitalization rates.

The company stated that Atacand is the first among ARB kinds to receive an indication t...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.